Coherus Oncology Inc reports results for the quarter ended June 30 - Earnings Summary

Coherus Oncology

08/08/2025 05:45

Coherus Oncology Inc CHRS.OQ reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -14 cents.  The mean expectation of five analysts for the quarter was for a loss of 32 cents per share. Wall Street expected results to range from -33 cents to -31 cents per share.

Revenue fell 84.2% to $10.25 million from a year ago; analysts expected $10.14 million.

Coherus Oncology Inc's reported EPS for the quarter was $2.57​.

The company reported quarterly net income of $297.77 million.

Coherus Oncology Inc shares had risen by 25.2% this quarter and lost 33.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 34.7% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Coherus Oncology Inc is $6.50, about 86.4% above its last closing price of $0.88

This summary was machine generated from LSEG data August 8 at 04:44 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.32
-0.34
Missed
Mar. 31 2025
-0.21
-0.35
Missed
Dec. 31 2024
-0.13
-0.28
Missed
Sep. 30 2024
-0.13
-0.01
Beat